Oxford Immunotec Global Stock Price, News & Analysis (NASDAQ:OXFD)

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its earnings results on Tuesday, August, 6th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.07. The company earned $19.60 million during the quarter, compared to the consensus estimate of $19.32 million. Oxford Immunotec Global had a net margin of 208.48% and a return on equity of 14.76%. Oxford Immunotec Global's quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) EPS. View Oxford Immunotec Global's Earnings History.

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Oxford Immunotec Global.

Oxford Immunotec Global issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $71-73 million, compared to the consensus revenue estimate of $70.57 million.

2 equities research analysts have issued 12 month target prices for Oxford Immunotec Global's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's share price to reach $20.00 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

Headlines about OXFD stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a news impact score of 2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Oxford Immunotec Global.

Oxford Immunotec Global saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 347,700 shares, an increase of 25.3% from the August 30th total of 277,600 shares. Based on an average trading volume of 182,500 shares, the short-interest ratio is presently 1.9 days. Currently, 1.3% of the shares of the company are short sold. View Oxford Immunotec Global's Current Options Chain.

Some companies that are related to Oxford Immunotec Global include Lantheus (LNTH), Heska (HSKA), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), GeneNews (GNWSF), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO) and Akers Biosciences (AKER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Immunomedics (IMMU), Intel (INTC), AbbVie (ABBV), Gold Resource (GORO), Sangamo Therapeutics (SGMO), Centurylink (CTL), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Advanced Micro Devices (AMD) and Abraxas Petroleum (AXAS).

Oxford Immunotec Global's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.09%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

OXFD stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OXFD stock can currently be purchased for approximately $15.36.

Oxford Immunotec Global has a market capitalization of $412.12 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]